Medication info
BILDAVSM 50/1000 mg (Vildagliptin, Metformin Hydrochloride) Tablets

BILDAVSM 50/1000 mg (Vildagliptin, Metformin Hydrochloride) Tablets

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Dark yellow oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202302591 · Approved 2023.08.30 · Insurance code 694004120

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin greater than 100mg per day are not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine is vildagliptin 100mg per day and the patient's current dose of metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their current doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and a dose of metformin similar to the patient's current dose. - When this medicine is used in combination with a sulfonylurea, the dose of the sulfonylurea may need to be reduced to lower the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic medicine to this medicine. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is already time for your next dose. Do not take a double dose at one time to make up for the missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help patients with type 2 diabetes who require a combination of vildagliptin and metformin for blood sugar control. It assists in effectively improving blood sugar levels in conjunction with dietary and exercise therapies.

How to take

Adult dose

For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin greater than 100mg per day are not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine is vildagliptin 100mg per day and the patient's current dose of metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their current doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and a dose of metformin similar to the patient's current dose. - When this medicine is used in combination with a sulfonylurea, the dose of the sulfonylurea may need to be reduced to lower the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic medicine to this medicine. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is already time for your next dose. Do not take a double dose at one time to make up for the missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal.

Precautions

This medication contains metformin and vildagliptin and is mainly used for the treatment of type 2 diabetes. It can cause severe lactic acidosis or hypoglycemia, so it should not be administered to patients with moderate or severe renal impairment or heart failure. Particularly in patients with abnormal renal function, cardiovascular collapse, acute myocardial infarction, or sepsis, this medication should not be used, and treatment should be temporarily discontinued before and after the administration of radiopaque iodine contrasts. It is also safe for pregnant or breastfeeding women to refrain from using this medication. Cautions should be taken as irregular meals, vigorous exercise, and interactions with other medications can increase the risk of hypoglycemia or lactic acidosis. During treatment, mild side effects such as headaches, dizziness, nausea, and hypoglycemia may occur, and if symptoms like abnormal liver function, skin rashes, or joint pain appear, immediate consultation with a physician is advisable. This medication is not suitable for patients with type 1 diabetes who require insulin therapy. If symptoms of acute pancreatitis occur, treatment should be stopped immediately, and due to the risk of lactic acidosis, treatment should be paused in the event of dehydration, severe diarrhea, vomiting, or fever, and medical personnel should be informed. Patients with impaired liver function and those who consume excessive alcohol should take caution when using this medication. Renal function should be regularly monitored, and treatment should be terminated if renal function declines. This medication can interact with various drugs, so patients taking other medications should inform their doctor or pharmacist and be managed carefully. Elderly individuals may have reduced renal function, so dosage adjustments and regular renal function tests are necessary. In the case of an overdose, supportive therapy is needed, and the metformin component can be removed through hemodialysis. When storing, keep in a place out of reach of children, and avoid transferring to another container. During the use of this medication, it is important to be fully aware of the symptoms of hypoglycemia or lactic acidosis and consult medical personnel immediately if symptoms appear.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • hepatitis
  • liver dysfunction
  • elevated transaminase levels
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
Show 27 more
  • nausea
  • hypoglycemia
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • blood sugar reduction
  • weakness
  • sweating
  • constipation
  • joint pain
  • upper respiratory infection
  • nasopharyngitis
  • peripheral edema
  • indigestion
  • abdominal discomfort
  • gastrointestinal abnormalities
  • increased serum amylase
  • increased lipase
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • severe and debilitating joint pain
  • cutaneous vasculitis
  • cholecystitis
  • vesicular pemphigoid

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is important to keep it in a cool place below 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Dark yellow oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.